Systemic lupus erythematosus: new diagnostic and therapeutic approaches
S Lazar, JM Kahlenberg - Annual review of medicine, 2023 - annualreviews.org
Systemic lupus erythematosus (SLE) is a devastating autoimmune disease that can result in
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …
substantial morbidity and mortality. Diagnosis and treatment of SLE are clinical challenges …
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal …
MF Ugarte-Gil, A Mak, J Leong… - Lupus science & …, 2021 - lupus.bmj.com
Objective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC)
exposure are known to contribute to irreversible organ damage. We aimed to examine the …
exposure are known to contribute to irreversible organ damage. We aimed to examine the …
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 …
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease
characterised by multisystem involvement. We aimed to evaluate the efficacy of anifrolumab …
characterised by multisystem involvement. We aimed to evaluate the efficacy of anifrolumab …
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
Background Systemic lupus erythematosus (SLE) management objectives include
preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the …
preventing disease flares while minimizing glucocorticoid exposure. Pooled data from the …
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
R Tummala, G Abreu, L Pineda, MA Michaels… - Lupus science & …, 2021 - lupus.bmj.com
Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We …
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort …
R Kandane-Rathnayake, V Golder… - The Lancet …, 2022 - thelancet.com
Background Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have
been validated to protect against organ damage and to improve quality of life. We aimed to …
been validated to protect against organ damage and to improve quality of life. We aimed to …
'Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study
R Kandane-Rathnayake, W Louthrenoo, A Hoi… - Arthritis Research & …, 2022 - Springer
Background The unmet need in systemic lupus erythematosus (SLE) with the current
standard of care is widely recognised, but few studies have quantified this. The recent …
standard of care is widely recognised, but few studies have quantified this. The recent …
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
Objectives In patients with systemic lupus erythematosus (SLE), lupus low disease activity
state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS …
state (LLDAS) attainment is associated with improved outcomes. We investigated LLDAS …
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Y Tanaka, R Tummala - Modern Rheumatology, 2021 - academic.oup.com
Chronic activation of the type I interferon (IFN) pathway plays a critical role in systemic lupus
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …
erythematosus (SLE) pathogenesis. Anifrolumab is a human monoclonal antibody to the …
Advances in the management of systemic lupus erythematosus
EF Morand, R Fernandez-Ruiz, A Blazer, TB Niewold - bmj, 2023 - bmj.com
Systemic lupus erythematosus (SLE) is a severe multisystem autoimmune disease that can
cause injury in almost every body system. While considered a classic example of …
cause injury in almost every body system. While considered a classic example of …